EP1259238A1 - Stable acid labile benzimidazole pharmaceutical compositions - Google Patents

Stable acid labile benzimidazole pharmaceutical compositions

Info

Publication number
EP1259238A1
EP1259238A1 EP00977823A EP00977823A EP1259238A1 EP 1259238 A1 EP1259238 A1 EP 1259238A1 EP 00977823 A EP00977823 A EP 00977823A EP 00977823 A EP00977823 A EP 00977823A EP 1259238 A1 EP1259238 A1 EP 1259238A1
Authority
EP
European Patent Office
Prior art keywords
composition according
vitamin
acid labile
derivative
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00977823A
Other languages
German (de)
French (fr)
Inventor
Arthur M. Deboeck
Francis Van Der Biest
Philippe R. Baudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GALEPHAR PHARMACEUTICAL RESEARCH Inc
Original Assignee
Baudier Philippe R
Van der Biest Francis
Deboeck Arthur M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baudier Philippe R, Van der Biest Francis, Deboeck Arthur M filed Critical Baudier Philippe R
Publication of EP1259238A1 publication Critical patent/EP1259238A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Definitions

  • the present invention provides for a stable oral pharmaceutical composition containing an acid labile benzimidazole compound as active ingredient.
  • the active ingredient in said formulation being stabilized which a vitamin E derivative.
  • the invention relates also to a cost effective manufacturing process for the preparation of said stable pharmaceutical dosage form. More particularly the manufacturing process comprises the filling in to gelatin and/or hydroxypropylmethylcellulose capsules of the mixed melted ingredients with the active drug. The capsules being thereafter optionally enteric coated.
  • Acid labile benzimidazole compounds comprise 2[2(pyridyl) methylsulfinyl] - benzimidazole or a derivative thereof (hereinafter sometimes referred to collectively as "benzimidazole compounds' " ) particularly the derivatives 2-[[3 methyl - 4 - (2,2,2 trifluoro methoxy) - 2 - pyridyl] methyl sulfinyl] benziminazole and 5 - methoxy - 2 - [(4 - methoxy - 3, 5 -dimethyl - 2 - pyridyl) methylsulfinyl] benzimidazole which are useful as anti-ulcer agent.
  • enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
  • enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
  • enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change.
  • Eudragit methacrylic acid-acrylic acid copolymer
  • US Patent 4786505 describes a pharmaceutical preparation containing omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally together with an alkaline compound as the core material, one or more sub-coating layer comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and enteric coating.
  • US Patent 5093132 describes a stabilized pharmaceutical composition
  • a stabilized pharmaceutical composition comprising: an effective amount of a 2-benzimidazole derivative selected from the group consisting of 2- benzimidazole and 5-methoxy-2-benzimidazole, or a pharmaceutically acceptable salt thereof; a basic inorganic salt stabilizing agent which is present in an amount effective to stabilize the composition, the benzimidazole derivative being in contact with the basic inorganic salt evenly; and an enteric coating for the composition.
  • US Patent 5385739 describes a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts.
  • US Patent 5399700 describes a method for stabilizing an acid-unstable compound by forming an inclusion complex of omeprazole with cyclodextrin comprising: dissolving cyclodextrin in an aqueous alkaline solution at 40° to 70 °C, and reacting said omeprazole with a cyclodextrin for 1 to 30 minutes in said alkaline solution, the ratio of said acid-ustable compound to said cyclodextrin in said reaction being from about 1 :1 to about 1 : 10, on a number of moles basis.
  • US Patent 5639478 describes a method of stabilizing an enteric coated anti-ulcer composition, which comprises: homogeneously admixing an effective amount of a 2-[(2- pyridyl) methylsulphinyl] -benzimidazole compound or a pharmaceutically acceptable salt thereof having a gastric acid secretion inhibitory property with a basic inorganic salt stabilizing agent; granulating the mixture; and enteric coating the granules.
  • US Patent 5626875 describes a stable oral pharmaceutical preparation containing an acid benzimidazole compound, which comprises: (a) A nucleus formed by an inert core, the acid labile benzimidazole compound, a non-alkaline inert water soluble polymer and non-alkaline reacting pharmaceutical acceptable excipients; (b) an inert non-alkaline coating disposed on said nucleus, formed by a non-alkaline water soluble polymer and non-alkaline pharmaceutical excipients. and (c) an outer layer disposed on the previous coating comprising an enteric coating.
  • the present inventors made investigations for a new cost efficient manufacturing process for the preparation of stable pharmaceutical formulations containing acid labile benzimidazole compounds and. as a result, have completed the present invention.
  • the object of the present invention is to obtain a pharmaceutical composition comprising an acid labile benzimidazole compound that possesses excellent storage stability.
  • Another object of the present invention is to obtain a stable benzimidazole compound pharmaceutical composition using a simplified and/or cost effective manufacturing process involving encapsulation into hard and/or soft gelatin and/or HPMC capsules of the molten excipients with the active benzimidazole compound.
  • Another object of the invention is to protect the formulation from the stomach acid juices by enteric coating the capsules.
  • the object of the present invention is to provide an oral enteric coated form of acid labile benzimidazole compounds, ensuring good stability and good bioavauability of said compounds and a simple and cost effective manufacturing process thereof.
  • the new dosage form is characterized in the following way: the acid labile benzimidazole compound is formulated in a semi-solid form containing a mixture of a lipophilic solubilising and/or supending inactive ingredients with a vitamin E derivative stabilizer. This liquids mix is then filled in to capsules. Which are thereafter enteric coated to protect the .benzimidazole compound from the gastric acids.
  • the present invention relates to a stable, gastro-enteric semi-solid formulation of acid labile benzimidazole compound providing a good bioavauability of the drug and a cost effective manufacturing process thereof.
  • the composition described comprises at least one lipophilic inactive ingredient and a derivate of «-tocopherol (Vitamin E) as stabilizing agent, in order to prevent the degradation of the acid labile benzimidazole compound.
  • the Vitamin E derivative may also acts as a co-solubilizer agent.
  • the lipophilic excipients chosen must allow the release of the acid labile benzimidazole compound very rapidly in the proximal parts of the small intestine, in order to obtain good bioavauability of the drug.
  • the acid labile benzimidazole compound is added and mixed to a molten mixture of excipients.
  • This mixture comprises the lipophilic constituents and the stabilizing agent.
  • the temperature of the mixture is maintained sufficiently high during the whole process to maintain the mixture in a liquid state. Capsules filled with the liquid mixture are thereafter enteric coated.
  • the benzimidazole compound for the use in this invention have potent gastric acid antisecretory activity, gastric mucosa-protecting activity and antiulcer activity and, yet, a low toxic potential and, therefore, can find application in the treatment of peptic ulcer in malian animals (e.g. mouse, rat, rabbit, dog, cat and man).
  • malian animals e.g. mouse, rat, rabbit, dog, cat and man.
  • the benzimidazole compounds having antiulcer activity for use in this invention includes, among specific examples, 2-[2-[3-methyl-4-2(2,2,2- trifluoroethoxy)pyridlyl]methylsulf ⁇ nyl]benzimidazole (lansoprazole), 2-[2-[3-methyl-4-(2,2,3,3- tetrafluoropropoxy)pyridyl]methylthio] benzimidazole, 2-[(2- pyridyl)methyldulifyl]benzimidazole (thimoprazole), 2-[2-(3,5-dimethyl-4- methoxypryridyI)methylsulfinyl]-5-methoxy-lH-benzimidazole (omeprazole), 2-[2-[4-(3- mehoxypropoxy)-3-methylpyridyl]methylsulfinyl — 1 H-benzimidazole, 2-[2-(3,4- dimethoxypyridyl)methyl
  • benzimidazole compounds for use in this invention may be present as racemates and/or as individual stereoisomers.
  • Lipophilic pharmaceutical acceptable excipients usefull for the present invention include vegetable and/or animal oils, and/or synthetic triglycerides.
  • the preferred oils are mono, di or triglycerides saturated or unsaturated fatty acids (e.g. palmitic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, linolenic acid, laurolenic acid. etc.).
  • Still more desirable are the triglycerides of C8 - C18 saturated fatty acids such as coconut oil (akomed®) hydrogenated soja bean oil (akosol®), synthetic triglyceride of saturated fatty acids (Gelucire 33/01).
  • the more desirable lipohilic pharmaceutical acceptable excipient usefull for the present invention can be. at least partially, characterized by a low hydroxyl and iodine values.
  • the stabilizing agent for use in this invention includes a vitamin E or Vitamin E derivative such as d or dl alpha tocopherol, d or dl alpha tocopherol acetate, d or dl alpha tocopherol acid succinate.
  • Vitamin E Polyethylene Glycol succinate vitamine E TPGS®kodak.
  • the enteric coating is applied onto the capsule after cooling.
  • the enteric polymer may be chosen among, but are not restricted to cellulose acetate phtalate, polyvinyl acetate phtalate, Hydroxypropylmethylcellulose phtalate. co-polymerized methacrylic acid or similar compounds widely used in the pharmaceutical industry to obtain enteric coatings.
  • the enteric dispersion may be either an aqueous dispersion (EUDRAGIT L30D-55 ® , Rohm- Pharma. SURRETERIC ® , Colorcon) or hydro-ethanolic dispersion and/or solutions (HP 50 ® and HP 55*, Shin-Etsu).
  • EUDRAGIT L30D-55 ® Rohm- Pharma. SURRETERIC ® , Colorcon
  • hydro-ethanolic dispersion and/or solutions HP 50 ® and HP 55*, Shin-Etsu
  • the enteric coating layer may contain a pharmaceutically acceptable plasticizer.
  • a pharmaceutically acceptable plasticizer such as for instance triacetic citric acid esters, dibutyl succinate, phtalic acid esters, propylene glycol, diethyltartarate, acetylated monoglycerides.
  • the preparation according to the invention consists in a stable semi-solid composition filled into capsules which are enteric coated.
  • the capsules obtained are insoluble in acidic media but are rapidly dissolved in neutral and alkaline media.
  • a process for the manufacturing of the oral dosage form represents a further aspect of the invention.
  • the simplicity and the low cost of the proposed process may indeed be considered as advantage in comparison to existing manufacturing processes.
  • the acid labile benzimidazole compound is incorporate to the molten mix, which contains the lipophilic inactive ingredients and the stabilizing agent. Once homogeneous, the liquid is filled into hard gelatin or HPMC capsules. The capsules are thereafter enteric-coated using a fluidzed bed coater and/or any other acceptable coating equipment.
  • Acid labile benzimidazole compound (omeprazole) in mixture with Soja oil.
  • lOg of omeprazole base is added to 190g Soja bean oil.
  • 200mg of the mixture is introduced in hard gelatine capsules.
  • omeprazole base 20g is added to a molten mixture of 150g of Soja oil and 75g of Vitamin E Polyethylene Glycol Succinate.
  • the capsules were stored at room temperature and after 1 week no change in color was detected, demonstrating good stability of the acid labile benzimidazole compound.
  • cample 4 20g of omeprazole base was added to a molten mixture of 150g of Soja oil and lOOg of Vitamin E Polyethylene Glycol Succinate. 270mg of the mixture was introduced into hard Hydroxypropylmethylcellulose capsules. The capsules were stored at room temperature and after 1 week no change of color was observed demonstrating good stability characteristics. cample 4:
  • a beaker In a beaker, add the olive oil and heat at 37°C. Start agitation, add the Vitamin E derivative and thereafter the omeprazole and continue mixing for about half hour. Fill gelatine capsules size 3 with 107.5mg of the hot mixture. The stability of these formulations were measured by observation of the color of the capsule content. It is known that omeprazole color changes from white to dark brown while degradating.
  • composition of formulation 4a Upon storage a room temperature, the composition of formulation 4a changed color after 2 days while the formulation 4b showed some color changes after 4 days, the composition of formulation 4c did not show any color change after 1 week.
  • example 5 were prepared as in example 4.
  • the formulation stability was evaluated by the color changes of the capsule content.
  • the capsules were stored at room temperature and observed daily for color change.
  • composition of example 5a had a light change in color after 4 days while composition of example 5b has a very light change in color after 6 days.
  • the composition of example 5c did not show any change of color after 2 weeks of observations.
  • Example 6 (capsules + coating):
  • the capsules were prepared using preparation method from example 4. Each capsule contained 20mg of omeprazole. Thereafter they were coated using a STREA1 fluidized bed coater with 20 % of dry coating of the following coating suspension:
  • Example 7 Upon coating capsules were dried in an oven at 35 °C for 8 hours. The capsules were further packaged in HDPE bottles containing 30 capsules and a 0.5g desiccant. These packaged capsules underwent a stability program at 25 °C and 60% relative humidity. The percent of omeprazole versus theoretical amount was determined and was found at 101% initially, 102% after 8 months and 102% after 14 months. These results demonstrate that the formulation of example 6 is stable.
  • Example 7 Example 7:
  • the hot liquid suspension is transferred to an encapsulating machine and filling hard gelatine capsules size #3 with 46mg (8mg of omeprazole) or 92mg (16mg of omeprazole) of blend is performed.
  • the enteric coated capsules are thereafter dried for about 8 hours in an oven at 35 °C.
  • the capsules are packaged in High Density Polyethylene bottles containing 30 capsules and 0.5g of desiccant.

Abstract

The present invention relates to a novel oral pharmaceutical stable formulation containing an acid labile benzimidazole compound, which is stabilized with a vitamin E derivative. More specifically, the composition comprises the acid labile benzimidazole compound in solution and/or suspension in oil and/or oil derivatives and a vitamin E derivative as stabilizer. A particular embodiment comprising omeprazole as acid labile benzimidazole compound and vitamin E Polyethylene glycol succinate as vitamin E stabilizer derivative is disclosed.

Description

Stable Acid Labile Benzimidazole Pharmaceutical Compositions
Summary of the invention
The present invention provides for a stable oral pharmaceutical composition containing an acid labile benzimidazole compound as active ingredient. The active ingredient in said formulation being stabilized which a vitamin E derivative.
The invention relates also to a cost effective manufacturing process for the preparation of said stable pharmaceutical dosage form. More particularly the manufacturing process comprises the filling in to gelatin and/or hydroxypropylmethylcellulose capsules of the mixed melted ingredients with the active drug. The capsules being thereafter optionally enteric coated.
Background of the invention
Acid labile benzimidazole compounds comprise 2[2(pyridyl) methylsulfinyl] - benzimidazole or a derivative thereof (hereinafter sometimes referred to collectively as "benzimidazole compounds'") particularly the derivatives 2-[[3 methyl - 4 - (2,2,2 trifluoro methoxy) - 2 - pyridyl] methyl sulfinyl] benziminazole and 5 - methoxy - 2 - [(4 - methoxy - 3, 5 -dimethyl - 2 - pyridyl) methylsulfinyl] benzimidazole which are useful as anti-ulcer agent. Those benzimidazole compounds, which are, descπbed in US Patent: 4,255,431 ; 4,555,518; 4.753,955; 4.824.856; 5.171 ,746: 5,149.702; 5.215.974; 5.504,082; 5,703.097; 5,693.818; 5.840.910; 5.916.904; respectively, among others are known to have anti-ulcer activity, and/or useful for the treatment of glaucoma, and/or psoriasis and DNA viral infection.
These compounds have however extremely poor stability properties. They are susceptible to heat, moisture and light and their stability decreases with decreasing pH values. In dosages form i.e. tablets, powders, fine granules, granules and capsules, said compounds are apt to interact with other components contained in said dosage forms and accordingly are in less stable state as compared with the case where they occur alone. Thus, the content decreases and the color changes significantly during the manufacturing process of dosage form and with the lapse of time. Microcrystalline cellulose, polyvinylpyrrolidone (PVP), carboxymethylcellulose calcium, polyethylene glycol 6000 and Pluronic F68 (polyoxyethylenepolyoxypropylene copolymer). for instance are dosage form components adversely affecting the stability of said compounds. Furthermore, in the case of coated tablets and coated granules among the above dosage forms, enteric coating bases such as cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate and Eudragit (methacrylic acid-acrylic acid copolymer) have poor compatibility with said compounds and cause content decrease and color change. Nevertheless, one or more of these components or ingredients, which, as mentioned above, can produce adverse effects on the stability of said compounds, are essential in the manufacture of oral preparations and therefore difficulties are inevitably encountered in dosage form manufacture.
US Patent 4786505 describes a pharmaceutical preparation containing omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally together with an alkaline compound as the core material, one or more sub-coating layer comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and enteric coating.
US Patent 4853230 describes the same solution to the stability problem as patent 4786505 but extend it to all acid labile compounds.
US Patent 5093132 describes a stabilized pharmaceutical composition comprising: an effective amount of a 2-benzimidazole derivative selected from the group consisting of 2- benzimidazole and 5-methoxy-2-benzimidazole, or a pharmaceutically acceptable salt thereof; a basic inorganic salt stabilizing agent which is present in an amount effective to stabilize the composition, the benzimidazole derivative being in contact with the basic inorganic salt evenly; and an enteric coating for the composition.
US Patent 5385739 describes a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts.
US Patent 5399700 describes a method for stabilizing an acid-unstable compound by forming an inclusion complex of omeprazole with cyclodextrin comprising: dissolving cyclodextrin in an aqueous alkaline solution at 40° to 70 °C, and reacting said omeprazole with a cyclodextrin for 1 to 30 minutes in said alkaline solution, the ratio of said acid-ustable compound to said cyclodextrin in said reaction being from about 1 :1 to about 1 : 10, on a number of moles basis.
US Patent 5639478 describes a method of stabilizing an enteric coated anti-ulcer composition, which comprises: homogeneously admixing an effective amount of a 2-[(2- pyridyl) methylsulphinyl] -benzimidazole compound or a pharmaceutically acceptable salt thereof having a gastric acid secretion inhibitory property with a basic inorganic salt stabilizing agent; granulating the mixture; and enteric coating the granules.
All the above patents, try to solve the lack of stability of acid labile benzimidazole compounds in pharmaceutical composition by mixing them with inorganic basic salts. Nevertheless the processes therein describe require multiple coatings. These processes are extremely time consuming and therefore also very costly.
Another set of patents, US Pat 4,738,974; 5,690,960; 5, 714,504 avoids the above- mentioned stability problem by using said acid labile benzimidazole compounds in a salt form, say in the form of a lithium, sodium, potassium, magnesium, calcium or titanium salt.
However, the above prior art method requires, for the stabilization of the benzimidazole compounds, a step of converting said compounds to such a salt form as mentioned above prior to its use in the pharmaceutical preparation.
US Patent 5626875 describes a stable oral pharmaceutical preparation containing an acid benzimidazole compound, which comprises: (a) A nucleus formed by an inert core, the acid labile benzimidazole compound, a non-alkaline inert water soluble polymer and non-alkaline reacting pharmaceutical acceptable excipients; (b) an inert non-alkaline coating disposed on said nucleus, formed by a non-alkaline water soluble polymer and non-alkaline pharmaceutical excipients. and (c) an outer layer disposed on the previous coating comprising an enteric coating.
The prior art teachings, to resolve the lack of stability of benzimidazole acid labile compounds pharmaceutical preparations, involve all a large amount of time consuming and complex steps therefore rendering such manufacturing process extremely costly.
In view of the above, the present inventors made investigations for a new cost efficient manufacturing process for the preparation of stable pharmaceutical formulations containing acid labile benzimidazole compounds and. as a result, have completed the present invention.
Disclosure of the invention
The object of the present invention is to obtain a pharmaceutical composition comprising an acid labile benzimidazole compound that possesses excellent storage stability.
Another object of the present invention is to obtain a stable benzimidazole compound pharmaceutical composition using a simplified and/or cost effective manufacturing process involving encapsulation into hard and/or soft gelatin and/or HPMC capsules of the molten excipients with the active benzimidazole compound.
It is also an object of the present invention to obtain a pharmaceutical dosage form comprising a benzimidazole compound for oral administration.
Another object of the invention is to protect the formulation from the stomach acid juices by enteric coating the capsules.
Outline of the invention
The object of the present invention is to provide an oral enteric coated form of acid labile benzimidazole compounds, ensuring good stability and good bioavauability of said compounds and a simple and cost effective manufacturing process thereof. The new dosage form is characterized in the following way: the acid labile benzimidazole compound is formulated in a semi-solid form containing a mixture of a lipophilic solubilising and/or supending inactive ingredients with a vitamin E derivative stabilizer. This liquids mix is then filled in to capsules. Which are thereafter enteric coated to protect the .benzimidazole compound from the gastric acids.
Detailed description of the invention
Semi-solid formulation
The present invention relates to a stable, gastro-enteric semi-solid formulation of acid labile benzimidazole compound providing a good bioavauability of the drug and a cost effective manufacturing process thereof. The composition described comprises at least one lipophilic inactive ingredient and a derivate of «-tocopherol (Vitamin E) as stabilizing agent, in order to prevent the degradation of the acid labile benzimidazole compound. The Vitamin E derivative may also acts as a co-solubilizer agent. The lipophilic excipients chosen must allow the release of the acid labile benzimidazole compound very rapidly in the proximal parts of the small intestine, in order to obtain good bioavauability of the drug.
In the preferred manufacturing process, the acid labile benzimidazole compound is added and mixed to a molten mixture of excipients. This mixture comprises the lipophilic constituents and the stabilizing agent. The temperature of the mixture is maintained sufficiently high during the whole process to maintain the mixture in a liquid state. Capsules filled with the liquid mixture are thereafter enteric coated.
The benzimidazole compound for the use in this invention have potent gastric acid antisecretory activity, gastric mucosa-protecting activity and antiulcer activity and, yet, a low toxic potential and, therefore, can find application in the treatment of peptic ulcer in mamalian animals (e.g. mouse, rat, rabbit, dog, cat and man).
The benzimidazole compounds having antiulcer activity for use in this invention includes, among specific examples, 2-[2-[3-methyl-4-2(2,2,2- trifluoroethoxy)pyridlyl]methylsulfιnyl]benzimidazole (lansoprazole), 2-[2-[3-methyl-4-(2,2,3,3- tetrafluoropropoxy)pyridyl]methylthio] benzimidazole, 2-[(2- pyridyl)methyldulifyl]benzimidazole (thimoprazole), 2-[2-(3,5-dimethyl-4- methoxypryridyI)methylsulfinyl]-5-methoxy-lH-benzimidazole (omeprazole), 2-[2-[4-(3- mehoxypropoxy)-3-methylpyridyl]methylsulfinyl — 1 H-benzimidazole, 2-[2-(3,4- dimethoxypyridyl)methylsulfinyl)-5-difluoromethoxy- 1 H-benzimidazole (pantoprozole), 4- methyl-3-(2,2,2-trifloroethoxy)-5H-pyrido[l ',2':4,5][l ,2,3]thiaziano[2,3-a]benzimidazol-13- iuum tetrafluoroborate and so non.
The benzimidazole compounds for use in this invention may be present as racemates and/or as individual stereoisomers.
Lipophilic pharmaceutical acceptable excipients usefull for the present invention include vegetable and/or animal oils, and/or synthetic triglycerides. The preferred oils are mono, di or triglycerides saturated or unsaturated fatty acids (e.g. palmitic acid, caprylic acid, capric acid, lauric acid, myristic acid, oleic acid, linolenic acid, laurolenic acid. etc.). Still more desirable are the triglycerides of C8 - C18 saturated fatty acids such as coconut oil (akomed®) hydrogenated soja bean oil (akosol®), synthetic triglyceride of saturated fatty acids (Gelucire 33/01).
The more desirable lipohilic pharmaceutical acceptable excipient usefull for the present invention can be. at least partially, characterized by a low hydroxyl and iodine values.
The stabilizing agent for use in this invention includes a vitamin E or Vitamin E derivative such as d or dl alpha tocopherol, d or dl alpha tocopherol acetate, d or dl alpha tocopherol acid succinate. The preferred is Vitamin E Polyethylene Glycol succinate (vitamine E TPGS®kodak).
Enteric coating
The enteric coating is applied onto the capsule after cooling. The enteric polymer may be chosen among, but are not restricted to cellulose acetate phtalate, polyvinyl acetate phtalate, Hydroxypropylmethylcellulose phtalate. co-polymerized methacrylic acid or similar compounds widely used in the pharmaceutical industry to obtain enteric coatings.
The enteric dispersion may be either an aqueous dispersion (EUDRAGIT L30D-55®, Rohm- Pharma. SURRETERIC® , Colorcon) or hydro-ethanolic dispersion and/or solutions (HP 50® and HP 55*, Shin-Etsu).
The enteric coating layer may contain a pharmaceutically acceptable plasticizer. such as for instance triacetic citric acid esters, dibutyl succinate, phtalic acid esters, propylene glycol, diethyltartarate, acetylated monoglycerides.
Thus, the preparation according to the invention consists in a stable semi-solid composition filled into capsules which are enteric coated. The capsules obtained are insoluble in acidic media but are rapidly dissolved in neutral and alkaline media.
Process
A process for the manufacturing of the oral dosage form represents a further aspect of the invention. The simplicity and the low cost of the proposed process may indeed be considered as advantage in comparison to existing manufacturing processes. Briefly, the acid labile benzimidazole compound is incorporate to the molten mix, which contains the lipophilic inactive ingredients and the stabilizing agent. Once homogeneous, the liquid is filled into hard gelatin or HPMC capsules. The capsules are thereafter enteric-coated using a fluidzed bed coater and/or any other acceptable coating equipment.
Example 1:
Acid labile benzimidazole compound (omeprazole) in mixture with Soja oil. lOg of omeprazole base is added to 190g Soja bean oil. 200mg of the mixture is introduced in hard gelatine capsules.
These capsules were stored at room temperature. After one week upon opening of said capsule the mixture color changed from white to deep brown showing degradation of omeprazole.
Example 2:
20g of omeprazole base is added to a molten mixture of 150g of Soja oil and 75g of Vitamin E Polyethylene Glycol Succinate.
245mg of the mixture is introduced in hard gelatine capsules.
The capsules were stored at room temperature and after 1 week no change in color was detected, demonstrating good stability of the acid labile benzimidazole compound.
Example 3:
20g of omeprazole base was added to a molten mixture of 150g of Soja oil and lOOg of Vitamin E Polyethylene Glycol Succinate. 270mg of the mixture was introduced into hard Hydroxypropylmethylcellulose capsules. The capsules were stored at room temperature and after 1 week no change of color was observed demonstrating good stability characteristics. cample 4:
4a 4b 4c
Omeprazole 10 10 10
Olive Oil 97.5 67.5 67.5
Tocopherol Acetate 0 30 0
Vitamin E Polyethylene
Glycol Succinate 0 0 30
Hard Gelatine fill weight [mg]: 107.5
In a beaker, add the olive oil and heat at 37°C. Start agitation, add the Vitamin E derivative and thereafter the omeprazole and continue mixing for about half hour. Fill gelatine capsules size 3 with 107.5mg of the hot mixture. The stability of these formulations were measured by observation of the color of the capsule content. It is known that omeprazole color changes from white to dark brown while degradating.
Upon storage a room temperature, the composition of formulation 4a changed color after 2 days while the formulation 4b showed some color changes after 4 days, the composition of formulation 4c did not show any color change after 1 week.
Example 5:
5a 5b 5c
Saturated Capric and 1,462.5 1,012.5 1,012.5
Caprilic triglycerides
(akomed®)
Omeprazole 150 150 150
Tocopherol Acetate 0 450 0
Vitamin E Polyethylene
Glycol Succinate 0 0 450
The Capsule fill weight [mg]: 107.5
The formulation of example 5 were prepared as in example 4.
The formulation stability was evaluated by the color changes of the capsule content. The capsules were stored at room temperature and observed daily for color change.
Composition of example 5a had a light change in color after 4 days while composition of example 5b has a very light change in color after 6 days. The composition of example 5c did not show any change of color after 2 weeks of observations.
Example 6 (capsules + coating):
Omeprazole micronized 0.104g
Medium chain triglyceride 0.347g
Vitamin E TPGS 0.149g
The capsules were prepared using preparation method from example 4. Each capsule contained 20mg of omeprazole. Thereafter they were coated using a STREA1 fluidized bed coater with 20 % of dry coating of the following coating suspension:
Hypromellose phtalate (HP50) 46.8g
Talc 28. lg
Glycerol Triacetate 1 1.7g
Red Iron Oxide 9.4g
Ethanol 734g
Water 129g
Upon coating capsules were dried in an oven at 35 °C for 8 hours. The capsules were further packaged in HDPE bottles containing 30 capsules and a 0.5g desiccant. These packaged capsules underwent a stability program at 25 °C and 60% relative humidity. The percent of omeprazole versus theoretical amount was determined and was found at 101% initially, 102% after 8 months and 102% after 14 months. These results demonstrate that the formulation of example 6 is stable. Example 7:
Capsule
Omeprazole 2.45kg
Medium chain triglyceride (akomed®) 8.16kg
Vitamin E TPGS 3.50kg
In a Fryma 20 liters mixer introduce the medium chain tryglyceride and warm at 40 °C under slow agitation for about 20 minutes. Add the molten vitamin E TPGS and mix for about 30 minutes maintaining temperature at 40 °C.
Add omeprazole micronized and mix for an additional 30 minutes.
The hot liquid suspension is transferred to an encapsulating machine and filling hard gelatine capsules size #3 with 46mg (8mg of omeprazole) or 92mg (16mg of omeprazole) of blend is performed.
Coating
Hypromellose phtalate (HP50) 1.872kg
Talc 1.124kg
Glycerol Triacetate 0.468kg
Red Iron Oxide 0.376kg
Ethanol 29.376kg
Water 5.184kg
In a stainless steel container equipped with a Silverson High shear mixer add Ethanol and Water. Start the mixer and add slowly hypromellose phtalate. Upon complete dissolution of the hypromellose phtalate add the glycerol triacetate, talc and red iron oxide. Mix at high speed for an additional 15 minutes. Place about 500g of capsules to be enteric coated in a fluridized bed coater STREA 1. Adjust inlet temperature at 40 °C and start coating at a spray rate of about lOg per minute. Apply coating until about 1kg of the coating suspension is dispensed.
The enteric coated capsules are thereafter dried for about 8 hours in an oven at 35 °C.
The capsules are packaged in High Density Polyethylene bottles containing 30 capsules and 0.5g of desiccant.

Claims

1. A stable oral pharmaceutical composition comprising an acid labile benzimidazole compound in mixture with at least a lipophilic pharmaceutical acceptable excipients and at least a Vitamin E derivative.
2. A composition according to claim 1 wherein the lipophilic pharmaceutical acceptable excipients are chosen among synthetic and/or animal and/or vegetable oils and their derivatives.
3. A composition according to claim 2 wherein the synthetic and/or animal and/or vegetable oil and their derivatives may be partially and/or fully hydrogenated.
4. A composition according to claim wherein the synthetic and/or animal and/or vegetable oil has an hydroxy value less than 30 and preferentially less than 10.
5. A composition according to claim 2 wherein the synthetic and/or animal and/or vegetable oil has an Iodine value of less than 10 and preferably less than 5.
6. A composition according to claim 1 wherein the Vitamin E derivative is d,l-«- tocopherol. d, 1 - -tocopherol acetate.
7. A composition according to claim 1 wherein the Vitamin E derivative is <* -tocopherol polyethyleneglycol succinate.
8. A composition according to claim 1 wherein the pharmaceutical composition consist of a hard gelatine or HPMC capsule.
9. A composition according to claim 1 wherein the capsule is enteric coated.
10. A composition according to claim 1 wherein the capsule is enteric coated using an aqueous or organic solution or suspension of one of the following polymer: cellulose acetate phtalate, Hydroxypropylmethylcellulose phtalate, polyvinyl acetate phtalate, co-polymerized methacrylic acid or similar compounds.
1 1. A composition according to claim 1 wherein the plasticizer used in the enteric coating solution or suspension is chosen among the following: triacetic citric acid ester dibutyl succinate, phtalic acid esters, proplynene glycol, dithyltartrate, acetylated monoglycerides or similar compounds.
12. A composition according to claim 1 wherein the acid labile benzimidazole compound includes lansoprazole, rabeprazole, thimoprazole, omeprazole, pantoprazole, and other proton pump inhibitors of the pyridine-benzimidazole sulfinyl family.
EP00977823A 1999-11-22 2000-11-22 Stable acid labile benzimidazole pharmaceutical compositions Withdrawn EP1259238A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16676199P 1999-11-22 1999-11-22
US166761P 1999-11-22
PCT/IB2000/001842 WO2001037834A1 (en) 1999-11-22 2000-11-22 Stable acid labile benzimidazole pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EP1259238A1 true EP1259238A1 (en) 2002-11-27

Family

ID=22604612

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00977823A Withdrawn EP1259238A1 (en) 1999-11-22 2000-11-22 Stable acid labile benzimidazole pharmaceutical compositions

Country Status (4)

Country Link
EP (1) EP1259238A1 (en)
AU (1) AU1545301A (en)
CA (1) CA2392353A1 (en)
WO (1) WO2001037834A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010015143A1 (en) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stable liquid oily ready-to-use formulations, preparation thereof and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
HU215966B (en) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Oral multiple emulsion-preconcentrate containing cyclosporin
WO1999036060A1 (en) * 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0137834A1 *

Also Published As

Publication number Publication date
AU1545301A (en) 2001-06-04
WO2001037834A1 (en) 2001-05-31
CA2392353A1 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
EP1108425B1 (en) New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
EP1061920B1 (en) Pharmaceutical formulation comprising a 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
KR100510366B1 (en) gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations
US20070196486A1 (en) Stable oral formulation containing benzimidazole derivative
WO1999061022A1 (en) A stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole
JP2011157390A (en) Fine granule insoluble in gastric juice, and process for preparation and pharmaceutical preparation of the same
AU2002210284A1 (en) Stable oral formulation containing benzimidazole derivative
US20070196463A1 (en) Enteric Soft Gelatin Capsule Containing Esomerpazole And Method Of Preparation
WO2004098573A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
WO2005034924A1 (en) Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
EP1259238A1 (en) Stable acid labile benzimidazole pharmaceutical compositions
WO2004089333A2 (en) A stable benzimidazole formulation
KR100535228B1 (en) Process for the preparation of hardcapsule formulation containing lansoprazole

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GALEPHAR PHARMACEUTICAL RESEARCH, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DEBOECK, ARTHUR, M.

Inventor name: VAN DER BIEST, FRANCIS

Inventor name: BAUDIER, PHILIPPE, R.

17Q First examination report despatched

Effective date: 20050114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050726